Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Celcuity Inc. - Common Stock
(NQ:
CELC
)
60.46
+0.56 (+0.93%)
Delayed Quote
Updated: 11:57 AM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Celcuity Inc. - Common Stock
< Previous
1
2
3
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC
August 04, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm
August 04, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
August 03, 2026
From
Kirby McInerney LLP
Via
Business Wire
CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law
August 02, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
NASDAQ: CELC Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm
July 28, 2026
From
Kessler Topaz Meltzer & Check, LLP
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC
July 28, 2026
From
Pomerantz LLP
Via
GlobeNewswire
CELCUITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm
July 21, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC
July 21, 2026
From
Pomerantz LLP
Via
GlobeNewswire
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
January 08, 2026
From
Equity Insider
Via
GlobeNewswire
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
October 06, 2025
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:LPTX),(NASDAQ:IOBT),(NASDAQ:CELC),(NYSE:MAIA) EQNX::TICKER_END
Via
FinancialNewsMedia
Peraso (NASDAQ: PRSO) Powers Military, Nex-Gen Broadband Surge – Mag 7 Undercard VAPE CELC, CRVO – More Stocks Inside
July 28, 2025
Via
AB Newswire
Topics
Supply Chain
Celcuity Inc. Announces $50 Million Private Placement
October 18, 2023
Via
ACCESSWIRE
Celcuity Set to Join Russell 2000 and 3000 Indexes
June 20, 2023
Via
ACCESSWIRE
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
May 24, 2023
Via
ACCESSWIRE
Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates
May 15, 2023
Via
ACCESSWIRE
Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress
May 12, 2023
Via
ACCESSWIRE
Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call
May 08, 2023
Via
ACCESSWIRE
Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress
May 08, 2023
Via
ACCESSWIRE
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
April 18, 2023
Via
ACCESSWIRE
Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
Via
ACCESSWIRE
Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 23, 2023
Via
ACCESSWIRE
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call
March 16, 2023
Via
ACCESSWIRE
Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
March 15, 2023
Via
ACCESSWIRE
Celcuity to Participate in Cowen's 43rd Annual Health Care Conference
March 01, 2023
Via
ACCESSWIRE
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium
February 16, 2023
Via
ACCESSWIRE
Celcuity Closes $100 Million Private Placement
December 12, 2022
Via
ACCESSWIRE
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium
December 09, 2022
Via
ACCESSWIRE
Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer
December 07, 2022
Via
ACCESSWIRE
Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium
November 22, 2022
Via
ACCESSWIRE
Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference
November 10, 2022
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
